Document Detail


Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment.
MedLine Citation:
PMID:  10227604     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dopaminomimetic agents, which were rationally designed to reverse dopamine deficits in the substantia nigra and ventral tegmental area of the parkinsonian midbrain, effectively attenuate deficits in motor and non-motor behavior thought to be elicited by dopamine deficiencies in the striatal and frontal limbic regions, respectively. On the other hand, dopaminomimetic medications may also induce perturbations in postsynaptic peptides, causing dopaminergic hypersensitivity. Drug-induced chronic dopaminomimetic psychosis afflicts about one-fifth of PD patients on dopaminergic regimens. Although the long-held mechanism for psychosis in PD is excessive stimulation of mesocorticolimbic dopamine receptors, interactions between dopamine and serotonin, as well as participation of serotonin-modulated GABAergic neurons may also contribute to the pathophysiology. Reduction or withdrawal of anticholinergic agents, amantadine, and dopamine precursors or agonists constitutes a first approach to the problem but is often insufficient. Unfortunately, typical antipsychotic agents such as haloperidol, which selectively antagonizes dopamine D-2 receptors, can induce extrapyramidal syndromes such as tardive parkinsonism. On the other hand, emerging atypical neuroleptics such as clozapine, quetiapine, and olanzapine, which antagonize 5HT-2A receptors (among others), inhibit D-2 receptors to a lesser degree and exhibit selective binding to mesolimbic (vs. striatal) dopamine receptors. The limbic selectivity of these agents appears to be of greater magnitude than that typical of risperidone. In addition, the selective antiserotonergic agent ondansetron is a prospective therapeutic option. The pharmacologic properties of these agents are explored.
Authors:
E C Wolters
Related Documents :
19185034 - The azulene framework as a novel arene bioisostere: design of potent dopamine d4 recept...
7014214 - Dopamine neurons of the retina: a simple method system for studying synaptic regulatory...
12007744 - Local dopaminergic modulation of the motor activity induced by n-methyl-d-aspartate rec...
9526064 - Detection of mrnas and alternatively spliced transcripts of dopamine receptors in rat p...
15044054 - Effect of adrenomedullin on c-met receptor expression after reserpine-induced gastric d...
11474544 - Low ph modulation of recombinant vanilloid receptors and perivascular capsaicin-sensiti...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Neurology     Volume:  52     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1999  
Date Detail:
Created Date:  1999-05-10     Completed Date:  1999-05-10     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S10-3     Citation Subset:  AIM; IM    
Affiliation:
Graduate School Neurosciences Amsterdam, Research Institute Neurosciences VU, Department of Neurology AZVU, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiparkinson Agents / adverse effects*,  therapeutic use
Dopamine Agonists / adverse effects*,  therapeutic use
Humans
Parkinson Disease / diagnosis*,  drug therapy
Psychoses, Substance-Induced / etiology*
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 0/Dopamine Agonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Depression: impact and management by the patient and family.
Next Document:  Psychosis: impact on the patient and family.